Dr. Michael Manns on a Possible Link Between Hepatitis C and Hepatocellular Carcinoma

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in patients with squamous non–small cell lung cancer.

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old patient with lung-metastatic renal cell carcinoma.

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with transplant-eligible multiple myeloma and the data behind their decisions.

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic hepatocellular carcinoma.

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, particularly benefiting patients 60 and older.